Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

Cancer

Volumn 95, Issue 11, 2002, Pages 2373-2379

  Mace, Joseph ^a   Sybil Biermann, J ^b   Sondak, Vernon ^c   McGinn, Cornelius ^c   Hayes, Curtis ^c   Thomas, Dafydd ^c   Baker, Laurence ^c  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

C kit; Chemotherapy; Desmoid tumor; Imatinib mesylate; Platelet derived growth factor receptor (PDGFR ); Platelet derived growth factor receptor (PDGFR ); Tyrosine kinase inhibition

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DESMOID TUMOR; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENETIC PREDISPOSITION; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CASE REPORT; FIBROMA; FIBROMATOSIS, AGGRESSIVE; HUMAN; MALE; PIPERAZINES; PROTO-ONCOGENE PROTEIN C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED-GROWTH FACTOR BETA; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036890418     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11029     Document Type: Article

References (51)

1. Weiss SW, Goldblum JR. Fibromatosis. In: Enzinger FW, Weiss SW. Soft Tissue Tumors, 4th Ed. St. Louis: C.V. Mosby, 2001:309-346.
2. Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol. 1996;27:939-943.
3. Almon BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6:98-101.
4. Gurbuz AK, Giardello FM, Petersen GM, et al. Desmoid tumors in familial adenomatous polyposis. Gut. 1994;35: 377-381.
5. Klemmer S, Pascone L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet. 1987;28:385-392.
6. Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am J Hum Genet. 1962;14:376-390.
7. Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. Incidence, sex, age, and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77:665-673.
8. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The Desmoid tumor II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77:674-680.
9. Reitamo JJ, Scheinin TM, Hayry P. The desmoid tumors: New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151:230-237.
10. Tonelli F, Valanzano R, Brandi ML. Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: Results of an in vitro study. Surgery. 1994;115:473-479.
11. Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 1994;74:1271-1274.
12. Berk T, Bulow S, Cohen Z, et al. Surgical aspects of familial adenomatous polyposis. Int J Colorectal Dis. 1988;3:1-6.
13. Lotfi AM, Dozios RR, Gordon H, et al. Mesenteric fibromatosis complicating familial adenomatous polyposis: Predisposing factors and results of treatment. Int J Colorectal Dis. 1989;4:30-36.
14. Kulaylat MN, Karakousis CP, Keaney CM, McCorvey D, Bem J, Ambrus JL Sr. Desmoid tumour: A pleoimorphic lesion. Eur J Surg Oncol. 1999;25:487-497.
15. Waddell WR. Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3, 5-adenosine monophosphate. Ann Surg. 1975;85: 475-477.
16. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158-167.
17. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40:637-645.
18. Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys. 1997;39:659-665.
19. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42:1007-1014.
20. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors: Summary of 19 cases and review of the literature. Ann Surg. 1989;210:765-769.
21. Higaki S, Tateishi A, Ohno T, et al. Surgical treatment of extra-abdominal desmoid tumors (aggressive fibromatosis). Int Orthop. 1995;19:383-389.
22. Markhede G, Lundgren L, Bjurstam N, Berlin O, Stener B. Extra-abdominal desmoid tumors. Acta Orthop Scand. 1986; 57:1-7.
23. Plukker JT, van Oort I, Verney A, et al. Aggressive fibromatosis (non-familial desmoid tumor): Therapeutic problems and the role of adjuvant radiotherapy. Br J Surg. 1995;82: 510-514.
24. Rock MG, Pricthard DJ, Reiman HM, Soule EH, Brewster RC. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66:1369-1374
25. Nuyttens JJ, Rust PF, Thomas CR Jr., Turrisi AT III. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors. A comparative review of 22 articles. Cancer. 2000;88:1517-1523.
26. Khorsand J, Karakousis CP. Desmoid tumors and their management. Am J Surg. 1985;149:251-258.
27. Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor: Not a benign disease. Arch Surg. 1989;124:191-196.
28. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer. 1984;54: 2051-2055.
29. Waddel WR, Gerner RE, Reich MP. Nonsteroidal anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol. 1983;33:197-211.
30. Belliveau P, Graham AM. Mesenteric desmoid tumor in Gardner's syndrome treated by sulindac. Dis Colon Rectum. 1984;27:53-54.
31. Klein WA, Miller HH, Anderson M, DeCosse JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer. 1987;60:2863-2868.
32. Waddell WR, Kirsc WM. Testolactone, sulindac, warfarin, and vitamin K for unresectable desmoid tumors. Am J Surg. 1991;161:416-421.
33. Procter H, Singh L, Baum M, Brinkley D. Response of multicentric desmoid tumors to tamoxifen. Br J Surg. 1987;74: 401.
34. Kinzbrunner B, Kitter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer. 1983;52:2201-2204.
35. Weiss AJ, Lackman RD. Low dose chemotherapy for desmoid tumors in association with familial adenomatous polyposis: A report of three cases. Can J Surg. 1996;39:247-252.
36. Wilcken N, Tattersall MHN. Endocrine therapy for desmoid tumors. Cancer. 1991;68:1384-1388.
37. Brooks MD, Ebbs SR, Colletia AA, Baum M. Desmoid tumors treated with triphenylethylenes. Eur J Cancer. 1992;28A: 1014-1018.
38. Hamilton L, Blackstein M, Berk T, et al. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis: A report of three cases. Can J Surg. 1996;39:247-252.
39. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer. 1983;72:3244-3247.
40. Lynch HT, Fitzgibbons R Jr., Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable desmoid tumors in Gardner's syndrome. Dis Colon Rectum. 1994;37:260-267.
41. Seiter K, Kemeny N. Successful treatment of desmoid tumor with doxorubicin. Cancer. 1993;71:2242-2244.
42. Schnitzler M, Cohen Z, Blackstein M, et al. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis Colon Rectum. 1997;40:798-801.
43. Azzarelli A, Gronchi A, Bertulli, R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92:1259-1264.
44. Weiss AJ, Lackman RD. Low dose chemotherapy of desmoid tumors. Cancer. 1989;67:1192-1194.
45. Fernberg JO, Brosjo O, Larsson O, Soderlund V, Strander H. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol. 1999;38:971-972.
46. Carroll M, Ohno-Jones S, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-Abl, TEL-Abl, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
47. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myelogenous leukemia. N Engl J Med. 2001;344:1031-1037.
48. Buchdunger E, Cioffi CL, Law N, et al. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
49. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;346:472-480
50. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growth inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001; 92:354-360.
51. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623-626.